Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Assessment of lipid profile when using lipid-lowering therapy (statins) in patients with coronary atherosclerosis

https://doi.org/10.20996/1819-6446-2015-11-5-459-463

Full Text:

Abstract

Aim. To assess of lipid-lowering therapy with statins in very high cardiovascular risk patients admitted to hospital for coronary angiography and analyze lipid profiles depending on the intensity of lipid-lowering therapy.
Material and methods. A total of 502 patients aged 25-86 years (mean age 61.2±9.4 years) who admitted to the clinic of State Research Center for Preventive Medicine were consecutively included into the study. All of them were examined and underwent coronary angiography. Plasma lipid levels were determined by standard laboratory methods. Results. The levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-cholesterol) and non-high-density lipoprotein cholesterol (HDL-cholesterol) were significantly higher among patients not taking lipid-lowering therapy. 62.1% of patients having a non-intensive lipid-lowering therapy and 52.5% of the patients having intensive therapy reached the target level of TC for high-risk patients. However, only one third of patients reached the target TC level for patients at very high risk in these patient groups. Target level of LDL-cholesterol <1.8 mmol/l among all patients was reached only in 11.2% of patients treated with low doses and in 12.7% of patients treated with high doses of lipidlowering drugs. 
Conclusion. Dyslipidemia management in real clinical practice remains suboptimal, with a substantial proportion of patients fails to achieve guideline-recommended target lipid levels to reduce the risk of cardiovascular diseases and their complications.

About the Authors

N. E. Gavrilova
State Research Centre for Preventive Medicine. Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation


V. A. Metelskaya
State Research Centre for Preventive Medicine. Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation


E. B. Yarovaya
State Research Centre for Preventive Medicine. Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation


N. V. Gomyranova
State Research Centre for Preventive Medicine. Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation


S. A. Boytsov
State Research Centre for Preventive Medicine. Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation


References

1. Nichols M., Townsend N., Scarborough P., Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J 2014; 35:2950-9

2. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and treatment of High Blood Cholesterol in Adults (Adult Treatment Third Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-421

3. The national guidelines for the diagnosis and correction of lipid disorders for the prevention and treatment of atherosclerosis (V revision). Rossiyskiy Kardiologicheskiy Zhurnal 2012; 4 (Supplement 1): 132. In Russian (Национальные рекомендации по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза (V пересмотр). Российский Кардиологический Журнал 2012; 4 (Приложение 1): 1-32).

4. Dallmeier D., Koenig W. Strategies for vascular disease prevention: the role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2) and lipoprotein(a) (Lp(a)). Best Pract Res Clin Endicrinol Metab 2014; 28(3):281-94.

5. Gadi R., Figueredo V.M. Low-density lipoprotein cholesterol lowering therapies: what is on the horizon? J Cardiovasc Med 2015; 16(1):1-10.

6. Fruchart J.C., Davignon J., Hermans M.P., et al. Residual Risk Reduction Initiative (R3i). Residual macrovascular risk in 2013: what have we learned? Cardiovascular Diabetol 2014; 13:26-43.

7. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-504.

8. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trials. JAMA 2004; 291:1071-80.

9. Merkulov EV, Mironov VM, Samko AN Coronary angiography, ventriculography, shuntography in graphics and charts. Moscow: Media Medica; 2011. In Russian (Меркулов Е.В., Миронов В.М., Самко А.Н. Коронароангиография, вентрикулография, шунтография в иллюстрациях и схемах. Москва: Медиа Медика; 2011).

10. Gensini G. A more meaningful scoring system for determining the severity of coronary artery disease. Am J Cardiol 1983; 51:606.

11. Gavrilova NE, Metelskaya VA, Petrova NV et al. Compare scale Gensini in determining the severity of coronary atherosclerosis with SYNTAX score and quantification of coronary artery lesions. Rossiyskiy Kardiologicheskiy Zhurnal 2014; 110 (6): 24-9. In Russian (Гаврилова Н.Е., Метельская В.А., Перова Н.В. и др. Сравнение шкалы Gensini в определении выраженности коронарного атеросклероза со шкалой SYNTAX и количественным определением поражения коронарных артерий. Российский Кардиологический Журнал 2014; 110(6): 24-9).

12. Kones R., Rumana U. Current Treatment of Dyslipidemia: A New Paradigm for Statin Drug Use and the Need for Additional Therapies. Drugs 2015;75(11):1187-99.

13. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet 2010; 376:1670-81.

14. Simes R.J., Marschner I.C., Hunt D., et al. LIPID Study Investigators. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 2002; 105:1162-9.

15. Boekholdt S.M., Hovingh G.K., Mora S., et al. Very low levels of atherogenic lipoproteins and risk of cardiovascular events; a meta-analysis of statin trials. J Am Coll Cardiol 2014; 64 (5): 485-94.

16. Boekholdt S.M., Arsenault B.J., Mora S., et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012; 307:1302-9.

17. Wong N.D., Chuang J., Wong K., et al. Residual dyslipidemia among United States adults treated with lipid modifying therapy (data from National Health and Nutrition Examination Survey 2009-2010). M J Cardiol 2013; 112(3):373-9.


For citation:


Gavrilova N.E., Metelskaya V.A., Yarovaya E.B., Gomyranova N.V., Boytsov S.A. Assessment of lipid profile when using lipid-lowering therapy (statins) in patients with coronary atherosclerosis. Rational Pharmacotherapy in Cardiology. 2015;11(5):459-463. (In Russ.) https://doi.org/10.20996/1819-6446-2015-11-5-459-463

Views: 387


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)